A detailed history of Captrust Financial Advisors transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Captrust Financial Advisors holds 11,313 shares of ADPT stock, worth $65,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,313
Previous 10,294 9.9%
Holding current value
$65,841
Previous $33,000 21.21%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.34 - $3.96 $2,384 - $4,035
1,019 Added 9.9%
11,313 $40,000
Q1 2024

May 15, 2024

SELL
$2.88 - $4.8 $4,896 - $8,160
-1,700 Reduced 14.17%
10,294 $33,000
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.33 $1,864 - $2,872
539 Added 4.71%
11,994 $58,000
Q3 2023

Nov 14, 2023

SELL
$5.07 - $8.44 $3,751 - $6,245
-740 Reduced 6.07%
11,455 $62,000
Q2 2023

Aug 14, 2023

BUY
$6.19 - $8.78 $427 - $605
69 Added 0.57%
12,195 $81,000
Q1 2023

May 15, 2023

BUY
$7.8 - $10.11 $94,582 - $122,593
12,126 New
12,126 $107,000
Q3 2022

Nov 16, 2022

BUY
$6.5 - $12.67 $72,553 - $141,422
11,162 Added 966.41%
12,317 $88,000
Q2 2022

Aug 23, 2022

SELL
$6.4 - $14.73 $1,004 - $2,312
-157 Reduced 11.97%
1,155 $9,000
Q2 2022

Aug 16, 2022

SELL
$6.4 - $14.73 $1,382 - $3,181
-216 Reduced 14.14%
1,312 $11,000
Q1 2022

May 16, 2022

BUY
$10.12 - $28.9 $7,670 - $21,906
758 Added 98.44%
1,528 $21,000
Q4 2021

Feb 14, 2022

BUY
$25.17 - $36.85 $4,530 - $6,633
180 Added 30.51%
770 $22,000
Q2 2021

Aug 16, 2021

SELL
$32.22 - $44.59 $28,031 - $38,793
-870 Reduced 59.59%
590 $24,000
Q1 2021

May 17, 2021

BUY
$37.26 - $67.74 $10,060 - $18,289
270 Added 22.69%
1,460 $59,000
Q4 2020

Feb 16, 2021

SELL
$45.01 - $65.47 $270 - $392
-6 Reduced 0.5%
1,190 $70,000
Q3 2020

Nov 17, 2020

BUY
$35.79 - $48.81 $42,804 - $58,376
1,196 New
1,196 $59,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $832M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.